title: [Medical treatment of spinal cord injury in the acute stage].
abstract: OBJECTIVE
  To evaluate the effect on neurologic outcome and the safety of nimodipine (N), methylprednisolone (M), or both (MN) versus no medical treatment (P) in spinal cord injury at the acute phase.
  
  
  METHODS
  Prospective, randomized clinical trial.
  
  
  METHODS
  One hundred and six patients with a spinal trauma, including 48 with paraplegia and 58 with tetraplegia.
  
  
  METHODS
  After eligibility, patients were randomly allocated in one of the following groups: M = methylprednisolone 30 mg.kg-1 over 1 hour, followed by 5.4 mg.kg-1.h-1 for 23 hours, N = nimodipine 0.015 mg.kg-1.h-1 over 2 hours followed by 0.03 mg.kg-1.h-1 for 7 days, MN or P. Neurologic assessment (ASIA score) was performed by a senior neurologist before treatment and at the 1-year follow-up. Early spinal decompression and stabilization was performed as soon as possible after injury.
  
  
  RESULTS
  One hundred patients were reassessed at the 1-year follow-up. Neurologic improvement was seen in each group (P < 0.0001), however no neurologic benefit from treatment was observed. Infectious complications occurred more often in patients treated with M. Early surgery (49 patients), within the first 8 hours did not influence the neurologic outcome. The only predictor of the latter was the extent of the spinal injury (complete or incomplete lesion).
  
  
  CONCLUSIONS
  Currently, no evidence of the benefit of medical treatment in this indication is existing. Because of the lack of clinical studies proving efficacy of pharmacological treatment in this specific pathology, a systematic use of medications cannot be recommended.
authors.affiliation: Département des urgences, hôpital Pellegrin, Bordeaux, France.
authors.forename: M E
authors.initials: ME
authors.lastname: Petitjean
authors.forename: V
authors.initials: V
authors.lastname: Pointillart
authors.forename: F
authors.initials: F
authors.lastname: Dixmerias
authors.forename: L
authors.initials: L
authors.lastname: Wiart
authors.forename: F
authors.initials: F
authors.lastname: Sztark
authors.forename: P
authors.initials: P
authors.lastname: Lassié
authors.forename: M
authors.initials: M
authors.lastname: Thicoïpé
authors.forename: P
authors.initials: P
authors.lastname: Dabadie
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D009553:Nimodipine / Q000627:therapeutic use*; D010264:Paraplegia / Q000188:drug therapy; D011446:Prospective Studies; D011782:Quadriplegia / Q000188:drug therapy; D013119:Spinal Cord Injuries / Q000150:complications / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D002121:Calcium Channel Blockers; D009553:Nimodipine; D008775:Methylprednisolone